The Latest Cardiac and Vascular News
Analysis of open-label extension data demonstrated that bempedoic acid was generally well tolerated and demonstrated sustained efficacy with up to 2.5 years of continuous treatment May 02, 2022 08:00 ET | Source: Esperion Therapeutics, Inc. ANN ARBOR, Mich., May 02, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the publication of data […]
– The CLEAR ACS trial is designed to evaluate the efficacy of NEXLIZET on short-term LDL-C lowering following those with a recent ACS event and at very high risk of recurrent CV event in a diverse patient population that is often underrepresented in clinical trials – ANN ARBOR, Mich., […]
Analysis of pooled Phase 3 data demonstrated 26.5% reduction vs. placebo in LDL-C from bempedoic acid monotherapy and 39.2% reduction vs. placebo in LDL-C from bempedoic acid and ezetimibe fixed-dose combination in patients not taking statins ANN ARBOR, Mich., April 13, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced […]
New Analyses of thousands of patients spanning Phase 2 and pooled Phase 3 data demonstrate that NEXLETOL safely and significantly lowers LDL-C compared to placebo in patients with renal impairment or hypertension ANN ARBOR, Mich., April 03, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today presented two new analyses from […]
– Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022 – – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew 12% Sequentially to $12.2 Million in the Fourth Quarter 2021 and Over 200% for the Full Year 2021 – – Prescriptions Grew 9% […]
– Unprecedented CLEAR Outcomes Trial Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022; Achieved 85% MACE Accumulation in December – – Fourth-quarter 2021 U.S. Net Product Revenue Estimated Between $12.0 to $12.5 Million – – Company Reiterates Full-Year 2022 Operating Expense Guidance of $220 to […]
– Addition to management team brings experienced strategic legal counsel as Company nears pivotal milestones – ANN ARBOR, Mich., Jan. 04, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR), today announced the appointment of Benjamin O. Looker as general counsel as of January 1, 2022. Mr. Looker will serve as a […]
– Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth – – Unprecedented CLEAR Outcomes Study Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022; Achieved 80% MACE Accumulation in October – – U.S. Net Product Revenue […]
– U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew 67% Sequentially to $10.6 Million – – Growth Driven by Increase in Demand and Substantial Improvement in Net Price – – Prescriptions Grew 28% During the Quarter; More Than 47,800 Patients Have Filled a Prescription for […]
– Expansion of management team with proven leader in cardiovascular disease supports advancement of CLEAR Outcomes trial and ESPERION therapeutic pipeline – ANN ARBOR, Mich., June 28, 2021 (GLOBE NEWSWIRE) — ESPERION (NASDAQ: ESPR), today announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer, effective […]
